BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Beam Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$24.19+0.72 (+3.07%)
Close on Oct 19, 2026
- Market cap
- $2.52B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.79 (−6.89%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Beam Therapeutics Inc. grew revenue 158.9% to $156.04M over the twelve months to Jun 30, 2026. Free cash flow was -$372.77M.
Revenue
$156.04M
+158.9% vs. a year earlier
Operating income
-$378.02M
TTM Q2 2026
Free cash flow
-$372.77M
TTM Q2 2026
EPS, diluted
-$0.82
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.52B
- P/E ratio
- –
- Price to sales
- 16.17
- Price to book
- 2.36
- Dividend yield
- –
- Free cash flow yield
- -14.77%
Fundamentals
- Revenue
- $156.04M
- Net income
- -$85.43M
- EPS, diluted
- -$0.82
- Free cash flow
- -$372.77M
- Book value per share
- $10.23
- Diluted shares
- 104M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$156.04M+158.9% YoY
Operating income
-$378.02M
Net income
-$85.43M
EPS, diluted
-$0.82
Free cash flow
-$372.77M
Reported periodTrailing twelve months